Jiangsu Hengrui Pharmaceuticals (01276): RSS0393 ointment approved for clinical trials.

Jiangsu Hengrui Pharmaceuticals (01276) announced that recently, its subsidiary Ruishi Biopharmaceutical Co., Ltd. received the Drug Clinical Trial Approval Notice for the RSS0393 ointment issued by the National Medical Products Administration (referred to as the "NMPA"), and will soon carry out clinical trials. The RSS0393 ointment is a proprietary ointment developed by the company containing a small molecule PDE4 inhibitor. After application, it can relieve tissue damage and inflammation by inhibiting PDE4 activity in various cells. For atopic dermatitis, there are currently similar drugs on the market globally, including Arcutis' Roflumilast cream (ZORYVE), Pfizer's crisaborole ointment (EUCRISA), and Daiichi Sankyo's diflumoter soft ointment (MOIZERTO); crisaborole ointment has been approved for sale in China. According to the EvaluatePharma database, the global sales of Roflumilast cream and diflumoter ointment in 2024 were approximately 254 million USD. As of now, the total R&D investment in the RSS0393 ointment project is approximately 28.5 million RMB.